BACE1 inhibition was considered the most promising strategy for lowering Aβ burden in the brain of AD patients, but the adverse effects that led to the discontinuation of several clinical trials fell short of everybody’s expectations [18–20]. The gene discussed is BACE1; the disease is Alzheimer disease.